Spruce Biosciences Inc.
02/17/2026 | Press release | Distributed by Public on 02/17/2026 15:11
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 17, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 3:20 p.m. ET.
Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the Company's website for approximately 90 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.
View source version on businesswire.com : https://www.businesswire.com/news/home/20260217981476/en/
Media Carolyn Hawley
Inizio Evoke Comms
[email protected]
[email protected]
Investors Monique Kosse
Gilmartin Group
[email protected]
[email protected]
Source: Spruce Biosciences, Inc.
Spruce Biosciences Inc. published this content on February 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on February 17, 2026 at 21:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]